Progress in Cardiovascular Diseases
Volume 53, Issue 2 , Pages 121-129 , September 2010

Role of Biomarkers in Chemotherapy-Induced Cardiotoxicity

  • Daniela Cardinale

      Affiliations

    • Cardiology Unit, European Institute of Oncology, I.R.C.C.S, Milan, Italy
    • Corresponding Author InformationAddress reprint requests to Daniela Cardinale, MD, Laboratory Medicine Unit, European Institute of Oncology, I.R.C.C.S, Milan, Italy.
    • ,
  • Maria Teresa Sandri

      Affiliations

    • Laboratory Medicine Unit, European Institute of Oncology, I.R.C.C.S, Milan, Italy

References 

  1. Herbst RS, Bajorin DF, Bleiberg H, et al. Clinical cancer advances 2005: major research advances in cancer treatment, prevention, and screening. A report from the American Society of Clinical Oncology. J Clin Oncol. 2006;24:190–205
  2. Yeh ETH, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy. Diagnosis, pathogenesis and management. Circulation. 2004;109:3122–3131
  3. Barry E, Alvarez JA, Scully RE, et al. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother. 2007;8:1039–1058
  4. Jones RL, Ewer MS. Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. Expert Rev Anticancer Ther. 2006;6:1229–1249
  5. Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation. 2003;108:1146–1162
  6. Steinherz LJ, Graham T, Hurwitz R, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Children Cancer Study Group. Pediatrics. 1992;89:942–949
  7. Meinardi MT, Van der Graaf WTA, Van Veldhuisen DJ, et al. Detection of anthracycline-induced cardiotoxicity. Cancer Treat Rev. 1999;25:237–247
  8. Sabel MS, Levine EG, Hurd T, et al. Is MUGA scan necessary in patients with low-risk breast cancer before doxorubicin-based adjuvant therapy?. Am J Clin Oncol. 2001;24:425–428
  9. Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy. Clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55:213–220
  10. Healey Bird BRJ, Swain SM. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res. 2008;14:14–24
  11. Nielsen D, Jensen JB, Dombernowsky P, et al. Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer. J Clin Oncol. 1990;8:1806–1810
  12. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol. 2002;13:699–709
  13. Alpert JS, Thygesen K, Antman E, et al. Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36:959–969
  14. O'Brien PJ. Cardiac troponin is the most effective translational safety biomarker for myocardial injury in cardiotoxicity. Toxicology. 2008;245:206–218
  15. Seino Y, Tomita Y, Nagai Y, et al. Cardioprotective effects of ACE-inhibitor (Cilazapril) on adriamycin cardiotoxicity in spontaneous hypertensive rats. Circulation. 1993;88:I–633[abstract]
  16. Herman EH, Zhang J, Lipshultz SE, et al. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol. 1999;17:2237–2243
  17. Adamcová M, Simunek T, Kaiserová H, et al. In vitro and in vivo examination of cardiac troponins as biochemical markers of drug-induced cardiotoxicity. Toxicology. 2007;237:218–228
  18. Simunek T, Klimtova I, Adamcova M, et al. Cardiac troponin T as an indicator of reduced left ventricular contractility in experimental anthracycline-induced cardiomyopathy. Cancer Chemother Pharmacol. 2003;52:431–434
  19. Lipshultz SE, Rifai N, Sallan SE, et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation. 1997;96:2641–2648
  20. Cardinale D, Sandri MT, Martinoni A, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol. 2000;36:517–522
  21. Cardinale D, Sandri MT, Martinoni A, et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol. 2002;13:710–715
  22. Sandri MT, Cardinale D, Zorzino L, et al. Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin Chem. 2003;49:248–252
  23. Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of Troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109:2749–2754
  24. Auner HW, Tinchon C, Linkesch W, et al. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol. 2003;82:218–222
  25. Specchia G, Buquicchio C, Pansini N, et al. Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines. J Lab Clin Med. 2005;145:212–220
  26. Kilickap S, Barista I, Akgul E, et al. cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Ann Oncol. 2005;16:798–804
  27. Cipolla CM, Colombo A, Torrisi R, et al. Clinical and prognostic implications of early troponin I increase in trastuzumab induced cardiotoxicity. In: Accepted at the American College of Cardiology 59th Annual Scientific Session, March 14-16. 2010;
  28. Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114:2474–2481
  29. Dolci A, Dominici R, Cardinale D, et al. Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use. Am J Clin Pathol. 2008;130:688–695[Review]
  30. Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 1997;350:1349–1353
  31. Suzuki T, Hayashi D, Yamazaki T, et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J. 1998;136:362–363
  32. Nousiainen T, Jantunen E, Vanninen E, et al. Acute neurohumoral and cardiovascular effects of idarubicin in leukemia patients. Eur J Haematol. 1998;61:347–353
  33. Hayakawa H, Komada Y, Hirayama M, et al. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol. 2001;37:4–9
  34. Meinardi MT, Van Veldhuisen DJ, Gietema JA, et al. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol. 2001;19:2746–2753
  35. Nousiainen T, Vanninen E, Jantunen E, et al. Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. J Intern Med. 2002;251:228–234
  36. Poutanen T, Tikanoja T, Riikonen P, et al. Long-term prospective follow-up study of cardiac function after cardiotoxic therapy for malignancy in children. J Clin Oncol. 2003;21:2349–2356
  37. Daugaard G, Lassen U, Bie P, et al. Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur J Heart Fail. 2005;7:87–93
  38. Sandri MT, Salvatici M, Cardinale D, et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction?. Clin Chem. 2005;51:1405–1410
  39. Pinarli FG, Oğuz A, Tunaoğlu FS. Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy. Pediatr Blood Cancer. 2005;44:370–377
  40. Nakamae H, Tsumura K, Terada Y, et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer. 2005;104:2492–2498
  41. Pichon MF, Cvitkovic F, Hacene K, et al. Drug-induced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography. In Vivo. 2005;19:567–576
  42. Soker M, Kervancioglu M. Plasma concentrations of NT-pro-BNP and cardiac troponin-I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood malignancy. Saudi Med J. 2005;26:1197–1202
  43. Erkus B, Demirtas S, Yarpuzlu AA, et al. Early prediction of anthracycline induced cardiotoxicity. Acta Pedriatr. 2007;96:506–509
  44. Aggarwal S, Pettersen MD, Bhambhani K, et al. B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children. Pediatr Blood Cancer. 2007;49:812–816
  45. Ekstein S, Nir A, Rein AJ, et al. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children. J Pediatr Hematol Oncol. 2007;29:440–444
  46. Zver S, Zadnik V, Bunc M, et al. Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation. Int J Hematol. 2008;88:227–236
  47. Knobloch K, Tepe J, Lichtinghagen R, et al. Simultaneous hemodynamic and serological cardiotoxicity monitoring during immunotherapy with trastuzumab. Int J Cardiol. 2008;125:113–115
  48. Horacek JM, Pudil R, Jebavy L, et al. Assessment of anthracycline-induced cardiotoxicity with biochemical markers. Exp Oncol. 2007;29:309–313
  49. Dodos F, Halbsguth T, Erdmann E, et al. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clin Res Cardiol. 2008;97:318–326
  50. Broeyer FJ, Osanto S, Ritsema van Eck HJ, et al. Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy. J Cancer Res Clin Oncol. 2008;134:961–968
  51. Mavinkurve-Groothuis AM, Groot-Loonen J, Bellersen L, et al. Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines. Pediatr Blood Cancer. 2009;52:631–636
  52. Cil T, Kaplan AM, Altintas A, et al. Use of N-terminal pro-brain natriuretic peptide to assess left ventricular function after adjuvant doxorubicin therapy in early breast cancer patients: a prospective series. Clin Drug Investig. 2009;29:131–137
  53. Clerico A, Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of the cardiac natriuretic peptides: a review. Clin Chem. 2004;50:33–50
  54. Vittorini S, Prontera C, Zucchelli GC, et al. Cardiac natriuretic hormones: methodological aspects. Immuno-Analyse Biol Spec. 2007;22:209–272
  55. Vittorini S, Clerico A. Cardiovascular biomarkers: increasing impact of laboratory medicine in cardiologypractice. Clin Chem Lab Med. 2008;6:748–763
  56. ElGhandour AH, El Sorady M, Azab S, et al. Human heart-type fatty acid-binding protein as an early diagnostic marker of doxorubicin cardiac toxicity. Hematol Rev. 2009;e6:1
  57. Horacek JM, Tichy M, Pudil R, et al. Glycogen phosphorylase BB could be a new circulating biomarker for detection of anthracycline cardiotoxicity. Ann Oncol. 2008;19:1656–1657
  58. Mercuro G, Cadeddu C, Piras A, et al. Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. Oncologist. 2007;12:1124–1133
  59. Nuver J, Smit AJ, Sleijfer DT, et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer. 2004;40:701–706
  60. Vaughn DJ, Palmer SC, Carver JA, et al. Cardiovascular risk in long-term survivors of testicular cancer. Cancer. 2008;112:1949–1953
  61. Altena R, Perik P, van Veldhuisen DJ, et al. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol. 2009;10:391–399[Review]
  62. Wouters KA, Kremer LCM, Miller TL, et al. Protecting against anthracyclines-induced myocardial damage: a review of the most promising strategies. Br J Haematol. 2005;131:561–578
  63. Okumura K, Jin D, Takai S, et al. Beneficial effects of angiotensin-converting enzyme inhibition in adryamicin-induced cardiomyopathy in hamsters. Jpn J Pharmacol. 2002;88:183–188
  64. Tokudome T, Mizushige K, Noma T, et al. Prevention of doxorubicin (adriamycin)-induced cardiomyopathy by simultaneous administration of angiotensin-converting enzyme inhibitor assessed by acoustic densitometry. J Cardiovasc Pharmacol. 2000;36:361–368
  65. Vaynblat M, Shah HR, Bhaskaran D, et al. Simultaneous angiotensin converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin. Eur J Heart Fail. 2002;4:583–586
  66. Sacco G, Bigioni M, Evangelista S, et al. Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. Eur J Pharmacol. 2001;414:71–78
  67. Abd El-Aziz MA, Othman AI, Amer M, et al. Potential protective role of angiotensin-converting enzyme inhibitors captopril and enalapril against adriamycin-induced acute cardiac and hepatic toxicity in rats. J Appl Toxicol. 2001;21:469–473
  68. Maeda A, Honda M, Kuramochi T, et al. An angiotensin-converting enzyme inhibitor protects against doxorubicin-induced impairment of calcium handling in neonatal rat cardiac myocytes. Clin Exp Pharmacol Physiol. 1997;24:720–726
  69. Toko H, Oka T, Zou Y, et al. Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy. Hypertens Res. 2002;25:597–603
  70. Spallarossa P, Garibaldi S, Altieri P, et al. Carvedilol prevents doxorubicin-induced free radicals release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol. 2004;37:837–846
  71. Kalay N, Basar E, Ozdogru I, et al. Protective effects of carvedilol against anthracyclines-induced cardiomyopathy. J Am Coll Cardiol. 2006;48:2258–2262
  72. Youssef G, Links M. The prevention and management of cardiovascular complication of chemotherapy in patients with cancer. Am J Cardiovasc Drugs. 2005;5:233–243

 Statement of Conflict of Interest: see page 127.

PII: S0033-0620(10)00086-1

doi: 10.1016/j.pcad.2010.04.002

Progress in Cardiovascular Diseases
Volume 53, Issue 2 , Pages 121-129 , September 2010

Article Tools

* Image Usage & Resolution